Leading Chinese Vaccine Developer Sinovac Conducts Technical Exchanges With Gates Foundation On Rotavirus Vaccine
This article was originally published in PharmAsia News
Executive Summary
BEIJING - China's leading vaccine developer, Sinovac Biotech, is applying for Chinese regulatory approval to launch clinical trials for two new pneumococcal polysaccharides vaccines
You may also be interested in...
Asia Innovators: Singapore's Inviragen In Race With Sinovac For HFMD Vaccine
SINGAPORE - Inviragen (Singapore) Pte Ltd is recruiting patients for its Phase I clinical trial in Singapore for its hand, foot and mouth disease vaccine INV21
Asia Innovators: Singapore's Inviragen In Race With Sinovac For HFMD Vaccine
SINGAPORE - Inviragen (Singapore) Pte Ltd is recruiting patients for its Phase I clinical trial in Singapore for its hand, foot and mouth disease vaccine INV21
China's State FDA Gets WHO Nod For Vaccine Regulatory System; Opens Global Market For Chinese Vaccine Makers
SHANGHAI - China's State FDA now complies with international standards for vaccine regulation and Chinese vaccine makers are eligible to apply for World Health Organization prequalification of vaccine products, WHO announced March 1, the same day that China implemented its newly revised good manufacturing practices (GMP) guidelines